Ocular Hypertension, Vitreoretinal Disease
Conditions
Keywords
Intravitreal triamcinolone acetonide, Side-effects, Ocular hypertension, Glaucoma, Prevention, Vitreoretinal diseases requiring IVTA for treatment
Brief summary
Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA develop ocular hypertension after the drug is injected into the eye. Similar to IVTA, topically administered corticosteroids eye drops result in ocular hypertension in approximately 33% of the population. It is unknown whether identifying patients who develop ocular hypertension from topical corticosteroids could be used to identify patients who are at risk for injectable IVTA. Therefore, the purpose of this study is to evaluate the efficacy of topical prednisolone 1% four times daily for one month as a screening test to reduce the incidence and severity of ocular hypertension after IVTA injection.
Interventions
DRUGPrednisolone 1% topical eye drops
Prednisolone 1% 1gtt qid to the eye requiring IVTA
Sponsors
Sunnybrook Health Sciences Centre
Hotel Dieu Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with vitreoretinal disease for which IVTA has been chosen as treatment
Exclusion criteria
* \< 18 years old * Pregnancy * Breast feeding * hx of uveitis * hx of neovascularization of the iris or anterior chamber angle * hx of ocular herpes simplex keratitis * hx of glaucoma * Unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To detect a 60% or greater decrease of developing ocular hypertension (>20 mmHg) in the group of patients who received a trial of prednisolone 1% gtts x 4 weeks, compared the group who did not receive a trial of topical prednisolone. | Monthly for 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Visual Acuity | Monthly for 6 months |
| Incidence of other complications (cataract, retinal detachment, endophthalmitis) | Monthly for 6 months |
Countries
Canada
Contacts
Primary ContactKenneth Eng, MD, FRCSC
Backup ContactJeffery Gale, MD, FRCSC
Outcome results
None listed